Another key finding was that autopsy-confirmed FTLD variants displayed group-level biomarker patterns, including reduced CSF T-tau in FTLD-tau (PSP) and reduced CSF P-tau/T-tau and increased CSF NFL in FTLD-TDP. The gene discussed is NEFL; the disease is supranuclear palsy, progressive, 1.